Adaptive Biotechnologies Corporation
NASDAQ:ADPTBiotechnology
+$0.61 today
- Market cap
- $4.61B
- Beta
- 2.15
- P/E (TTM)
- -54.5
- EPS (TTM)
- -$0.32
Volume 2.21M
Average 1.94M
ADPT Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Adaptive Biotechnologies CorporationNASDAQ: ADPT
Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026
Depreciation & amortization declines year over year
Q2 FY2026 depreciation & amortization of $3.7M fell 17.9% year over year, behind the -11.7% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 3.7% from the prior quarter. Over 3 fiscal years it compounded at -5.2% a year.
Context
- Depreciation & amortization amounted to 6.4% of revenue in FY2025, down 4.3 pp from a year earlier.
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -17.9% toward the trailing-twelve-month pace of -11.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 17.83M USD
- Year-over-year change
- -7.4%
- 4-year CAGR
- +6.3%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 17.83M | -7.4% |
| FY2024 | 2024-12-31 | 19.26M | -13.4% |
| FY2023 | 2023-12-31 | 22.23M | +6.3% |
| FY2022 | 2022-12-31 | 20.92M | +49.9% |
| FY2021 | 2021-12-31 | 13.95M | — |
Depreciation & Amortization vs competitors
How ADPT compares with its peers on the latest reported figures
- ADPT's LTM Jun 2026 depreciation & amortization of $16.13M is the 4th highest of the 10 companies compared; the peer median is $4.6M.
- Its year-over-year change of -11.7% is the 8th highest of 10, against a peer median of +7.7%.
- Depreciation & amortization amounts to 5.2% of revenue for ADPT, versus a peer median of 3.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $50.27M | +111.9% | +16.3% | 3.7% | |
| LTM Mar 2026 | $38.26M | +1.2% | +212.7% | 6.4% | |
| LTM Jun 2026 | $22.24M | +1.2% | +16.4% | 14.3% | |
| LTM Jun 2026 | $16.13M | -11.7% | -5.2% | 5.2% | |
| LTM Jun 2026 | $15.93M | +21.7% | +22.2% | 3.5% | |
| LTM Mar 2026 | $4.6M | +18.5% | +29.8% | 2.0% | |
| LTM Sep 2026 | $1.88M | +7.7% | +77.3% | 0.3% | |
| LTM Sep 2026 | $1.32M | -19.2% | -17.8% | 230.7% | |
IRONDisc Medicine, Inc. | LTM Sep 2026 | $358K | +78.1% | +46.7% | — |
| LTM Jun 2026 | $39K | -31.6% | — | — | |
| Peer median (excluding ADPT) | $4.6M | +7.7% | +26.0% | 3.7% | |
Competitors are the stored peer set for ADPT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 154.34M | 185.31M | 170.28M | 178.96M | 276.98M |
| Cost of Revenue | 49.3M | 57.91M | 75.55M | 72.08M | 71.36M |
| Gross Profit | 105.04M | 127.4M | 94.72M | 106.88M | 205.62M |
| Gross Margin | 68.1% | 68.7% | 55.6% | 59.7% | 74.2% |
| Research & Development | 142.34M | 141.76M | 122.12M | 102.95M | 93.77M |
| Selling, General & Admin | 169.97M | 184.13M | 172.51M | 157.57M | 167.27M |
| Operating Expenses | 314.01M | 327.59M | 321.76M | 269.43M | 262.74M |
| Depreciation & Amortization | 13.95M | 20.92M | 22.23M | 19.26M | 17.83M |
| EBITDA | (193.35M) | (175.21M) | (189.27M) | (128.76M) | (29.85M) |
| EBITDA Margin | -125.3% | -94.6% | -111.2% | -71.9% | -10.8% |
| Operating Income | (208.97M) | (200.19M) | (227.04M) | (162.55M) | (57.12M) |
| Operating Margin | -135.4% | -108.0% | -133.3% | -90.8% | -20.6% |
| Interest Income | 1.67M | 4.06M | 15.53M | 14.53M | 9.44M |
| Interest Expense | 0 | 4.24M | 13.8M | 11.58M | 11.78M |
| Other Income / Expenses | 1.67M | (182K) | 1.73M | 2.95M | (2.33M) |
| Income Before Tax | (207.3M) | (200.37M) | (225.3M) | (159.6M) | (59.46M) |
| Pre-Tax Margin | -134.3% | -108.1% | -132.3% | -89.2% | -21.5% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (207.28M) | (200.19M) | (225.25M) | (159.49M) | (59.5M) |
| Net Margin | -134.3% | -108.0% | -132.3% | -89.1% | -21.5% |
| EPS (Basic) | (1.46) | (1.00) | (1.56) | (1.08) | (0.39) |
| EPS (Diluted) | (1.46) | (1.00) | (1.56) | (1.08) | (0.39) |
| Weighted Avg Shares | 140.35M | 142.52M | 144.38M | 147.1M | 151.72M |
| Weighted Avg Shares (Diluted) | 140.35M | 142.52M | 144.38M | 147.1M | 151.72M |
Adaptive Biotechnologies Corporation
NASDAQ:ADPT
Intrinsic Alpha fair value
Locked
Current Price
$28.46
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.